Intimation is hereby given that the Officials of the Company will be participating in the Conference / Meeting scheduled on Emerging India CEO Forum by Nuvama on Monday, September 28, 2026.

Novartis India Limited September 23, 2026 The Secretary, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 500672 Subject : Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding Intimation for Participation in Investor Conferences Dear Sir / Madam, Pursuant to Regulation 30 read with Schedule III of the SEBI(LODR) regulation, 2015, as amended from time to time (“Listing Regulations”), we wish to inform you that the official(s) of the company will be meeting certain Investors/Analysts (Participants) at the Investor Conference. Meeting Day/Date Investor/ Analyst/ Event Location Type of Meeting format Monday, 1 X 1 and / or Nuvama – Emerging India September 28, Mumbai In-person Group CEO Forum 2026 Meetings The company will not be disclosing any Unpublished Price Sensitive Information (UPSI) at these meeting. The schedule of the above-mentioned meeting is subject to change, and the change may occur due to exigencies on either side. We request you to take this intimation on record. Thanking You, Yours Faithfully, For Novartis India Limited Chandni Maru Company Secretary and Compliance Officer A60291 Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in